Antibe Therapeutics Inc (ATBPF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
(Values in U.S. thousands)
| 12-2013 | 09-2013 | 06-2013 | |
| Operating Expenses | 904 | 524 | 304 |
| Operating Income | -904 | -524 | -304 |
| Interest Expense | 0 | 0 | 15 |
| Other Income | 0 | 0 | 15 |
| Pre-tax Income | -904 | -524 | -304 |
| Net Income Continuous | -904 | -524 | -304 |
| Net Income | $-904 | $-524 | $-304 |
| EPS Basic Total Ops | -0.29 | -0.19 | -0.20 |
| EPS Basic Continuous Ops | -0.33 | -0.20 | -0.15 |
| EPS Diluted Total Ops | -0.29 | -0.19 | -0.20 |
| EPS Diluted Continuous Ops | -0.33 | -0.20 | -0.15 |
| EBITDA(a) | $-904 | $-524 | $-289 |